The content on this site is intended for healthcare professionals only
Prof Stilgenbauer presents, at a press conference at ASH 2015, results of the pivotal international phase II study.
Venetoclax monotherapy induces deep remissions, including complete remission and undetectable mrd, in ultra-high risk relapsed/refractory chronic lymphocytic leukaemia with 17p deletion.
Read the news story and watch the video interview for more information.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM
Importance of MRD in newly developed multiple myeloma
Best practice in HRRm testing in patients with metastatic prostate cancer
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
